Skip to main content

Table 4 Treatment-related non-hematologic adverse events

From: Chidamide, decitabine, cytarabine, aclarubicin, and granulocyte colony-stimulating factor (CDCAG) in patients with relapsed/refractory acute myeloid leukemia: a single-arm, phase 1/2 study

AE*

Any grade AE, N (%)

Grade 3/4 AE, N (%)

Any AE

93 (100.0)

59 (63.4)

 Infection**

43 (46.2)

25 (26.9)

 Nausea

41 (44.1)

0 (0.0)

 Fatigue

31 (33.3)

1 (1.1)

 Vomiting

31 (33.3)

1 (1.1)

 Hypokalemia

29 (31.2)

9 (9.7)

 Hypoalbuminemia

25 (26.9)

0 (0.0)

 Febrile neutropenia

23 (24.7)

23 (24.8)

 Pneumonia

21 (22.6)

13 (14.0)

 Hypocalcemia

18 (19.4)

1 (1.1)

 Cough

17 (18.3)

0 (0.0)

 Hyponatremia

16 (17.2)

2 (2.2)

 Abdominal pain

14 (15.1)

0 (0.0)

 Pharyngalgia

14 (15.1)

1 (1.1)

 Anorexia

12 (12.9)

2 (2.2)

 Diarrhea

10 (10.8)

0 (0.0)

  1. Abbreviations: AE adverse event
  2. *AEs were assessed based on the CTCAE (NCI Common Terminology Criteria for Adverse Events) version 5.0 and are shown with a frequency ≥ 10%
  3. **Infection included pneumonia